Dear Colleagues,

Four promising technologies are one step closer to the marketplace thanks to funding from the University City Science Center’s QED Proof-of-Concept Program. Life science and health IT researchers from Drexel University, Temple University and Rutgers, The State University of New Jersey, received a total of $600,000 through the QED program to develop a potential drug therapy for Lou Gehrig’s disease; validate a new therapeutic compound for pancreatic cancer; develop software to analyze EEG readings and guide diagnosis; and improve communications skills of health care professionals.

Details are included in the attached press release which was distributed via Business Wire. To view the release online go to: http://www.businesswire.com/news/home/20131203006563/en

Best,

Jeanne

 

Jeanne Mell
VP Marketing Communications
University City Science Center
3711 Market Steet, Suite 800
Philadelphia, PA 19104
215.966.6029
[email protected]